Axon Enterprise, Inc (NASDAQ:AXON) Shares Purchased by PFG Advisors

PFG Advisors raised its position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 57.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,305 shares of the biotechnology company's stock after acquiring an additional 837 shares during the period. PFG Advisors' holdings in Axon Enterprise were worth $1,212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC grew its stake in shares of Axon Enterprise by 3.7% during the fourth quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company's stock valued at $1,095,542,000 after buying an additional 65,097 shares during the last quarter. Capital World Investors grew its position in Axon Enterprise by 86.4% in the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock valued at $1,079,145,000 after acquiring an additional 841,772 shares during the last quarter. Alliancebernstein L.P. increased its stake in Axon Enterprise by 273.8% in the fourth quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock worth $659,128,000 after purchasing an additional 812,337 shares during the period. Norges Bank bought a new stake in shares of Axon Enterprise during the fourth quarter worth $482,081,000. Finally, GAMMA Investing LLC boosted its position in Axon Enterprise by 58,725.5% in the 1st quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock valued at $402,210,000 after buying an additional 763,431 shares during the period. 79.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on AXON shares. JPMorgan Chase & Co. lifted their price target on shares of Axon Enterprise from $730.00 to $850.00 and gave the company an "overweight" rating in a research note on Thursday, July 17th. Morgan Stanley set a $885.00 target price on shares of Axon Enterprise and gave the company an "overweight" rating in a research report on Friday, July 11th. Needham & Company LLC upped their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Barclays lifted their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Finally, Bank of America upped their target price on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a report on Wednesday, June 4th. One analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $772.08.

Insider Activity at Axon Enterprise

In other news, Director Caitlin Elizabeth Kalinowski sold 1,300 shares of the stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $738.84, for a total transaction of $960,492.00. Following the sale, the director directly owned 4,829 shares of the company's stock, valued at $3,567,858.36. This represents a 21.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Jennifer H. Mak sold 75 shares of the business's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $771.81, for a total transaction of $57,885.75. Following the completion of the sale, the chief accounting officer directly owned 15,240 shares of the company's stock, valued at approximately $11,762,384.40. The trade was a 0.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,642 shares of company stock valued at $25,090,528 in the last quarter. 4.40% of the stock is currently owned by insiders.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock traded up $25.75 during trading on Friday, hitting $735.01. 654,601 shares of the company's stock were exchanged, compared to its average volume of 627,317. The stock has a market capitalization of $57.22 billion, a price-to-earnings ratio of 177.54, a PEG ratio of 81.93 and a beta of 1.29. The business has a 50-day simple moving average of $763.82 and a 200-day simple moving average of $650.93. Axon Enterprise, Inc has a 52-week low of $279.02 and a 52-week high of $830.21. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.62 and a current ratio of 2.83.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.07. The business had revenue of $603.63 million during the quarter, compared to analysts' expectations of $585.67 million. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The company's revenue for the quarter was up 31.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.15 EPS. On average, research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.